OBP-301
Undisclosed (Likely Liver Disease or Oncology)
NDA SubmittedSubmitted to Japan's PMDA
Key Facts
Indication
Undisclosed (Likely Liver Disease or Oncology)
Phase
NDA Submitted
Status
Submitted to Japan's PMDA
Company
About Medigen (2)
Taiwanese biotech company developing innovative cancer therapies and vaccines, with an integrated portfolio spanning drug development, diagnostics, and generics.
View full company profile